HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time

被引:2699
作者
Perelson, AS
Neumann, AU
Markowitz, M
Leonard, JM
Ho, DD
机构
[1] AARON DIAMOND AIDS RES CTR,NEW YORK,NY 10016
[2] LOS ALAMOS NATL LAB,DIV THEORET,LOS ALAMOS,NM 87545
[3] ABBOTT LABS,DIV PHARMACEUT PROD,ABBOTT PK,IL 60064
关键词
D O I
10.1126/science.271.5255.1582
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
A new mathematical model was used to analyze a detailed set of human immunodeficiency virus-type 1 (HIV-1) viral load data collected from five infected individuals after the administration of a potent inhibitor of HIV-1 protease. Productively infected cells were estimated to have, on average, a life-span of 2.2 days (half-life t(1/2) = 1.6 days), and plasma virions were estimated to have a mean life-span of 0.3 days (t(1/2) = 0.24 days). The estimated average total HIV-1 production was 10.3 x 10(9) virions per day, which is substantially greater than previous minimum estimates. The results also suggest that the minimum duration of the HIV-1 life cycle in vivo is 1.2 days on average, and that the average HIV-1 generation time-defined as the time from release of a virion until it infects another cell and causes the release of a new generation of viral particles-is 2.6 days, These findings on viral dynamics provide not only a kinetic picture of HIV-1 pathogenesis, but also theoretical principles to guide the development of treatment strategies.
引用
收藏
页码:1582 / 1586
页数:5
相关论文
共 15 条
[1]   CLINICAL-EVALUATION OF BRANCHED DNA SIGNAL AMPLIFICATION FOR QUANTIFYING HIV TYPE-1 IN HUMAN PLASMA [J].
CAO, YZ ;
HO, DD ;
TODD, J ;
KOKKA, R ;
URDEA, M ;
LIFSON, JD ;
PIATAK, M ;
CHEN, S ;
HAHN, BH ;
SAAG, MS ;
SHAW, GM .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1995, 11 (03) :353-361
[2]   QUANTITATIVE-ANALYSIS OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1)-SPECIFIC CYTOTOXIC LYMPHOCYTE-T (CTL) RESPONSE AT DIFFERENT STAGES OF HIV-1 INFECTION - DIFFERENTIAL CTL RESPONSES TO HIV-1 AND EPSTEIN-BARR-VIRUS IN LATE DISEASE [J].
CARMICHAEL, A ;
JIN, X ;
SISSONS, P ;
BORYSIEWICZ, L .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 177 (02) :249-256
[3]   HIV POPULATION-DYNAMICS IN-VIVO - IMPLICATIONS FOR GENETIC-VARIATION, PATHOGENESIS, AND THERAPY [J].
COFFIN, JM .
SCIENCE, 1995, 267 (5197) :483-489
[4]  
Efron B., 1986, Statistical science, V1, P54, DOI 10.1214/ss/1177013815
[5]   RAPID TURNOVER OF PLASMA VIRIONS AND CD4 LYMPHOCYTES IN HIV-1 INFECTION [J].
HO, DD ;
NEUMANN, AU ;
PERELSON, AS ;
CHEN, W ;
LEONARD, JM ;
MARKOWITZ, M .
NATURE, 1995, 373 (6510) :123-126
[6]   QUANTITATION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 IN THE BLOOD OF INFECTED PERSONS [J].
HO, DD ;
MOUDGIL, T ;
ALAM, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (24) :1621-1625
[7]   TIME TO HIT HIV, EARLY AND HARD [J].
HO, DD .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (07) :450-451
[8]   ABT-538 IS A POTENT INHIBITOR OF HUMAN-IMMUNODEFICIENCY-VIRUS PROTEASE AND HAS HIGH ORAL BIOAVAILABILITY IN HUMANS [J].
KEMPF, DJ ;
MARSH, KC ;
DENISSEN, JF ;
MCDONALD, E ;
VASAVANONDA, S ;
FLENTGE, CA ;
GREEN, BE ;
FINO, L ;
PARK, CH ;
KONG, XP ;
WIDEBURG, NE ;
SALDIVAR, A ;
RUIZ, L ;
KATI, WM ;
SHAM, HL ;
ROBINS, T ;
STEWART, KD ;
HSU, A ;
PLATTNER, JJ ;
LEONARD, JM ;
NORBECK, DW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (07) :2484-2488
[9]   LOWER IN-VIVO MUTATION-RATE OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 THAN THAT PREDICTED FROM THE FIDELITY OF PURIFIED REVERSE-TRANSCRIPTASE [J].
MANSKY, LM ;
TEMIN, HM .
JOURNAL OF VIROLOGY, 1995, 69 (08) :5087-5094
[10]  
MARKOWITZ M, 1995, NEW ENGL J MED, V333, P1534, DOI 10.1056/NEJM199512073332304